<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193920</url>
  </required_header>
  <id_info>
    <org_study_id>V98_08</org_study_id>
    <secondary_id>MCC Reference n° 20100601</secondary_id>
    <nct_id>NCT01193920</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age</brief_title>
  <official_title>A Phase Ib/II Randomized, Observer-Blind, Controlled, Single Centre Study of a Trivalent Group B Streptococcus Vaccine in Healthy Non-Pregnant Women Leading Into a Dose-Ranging Study in Pregnant Women in South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine at
      one dose in healthy non pregnant women and then in three different doses in healthy pregnant
      women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentages of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Month After the Second Vaccination.</measure>
    <time_frame>Day 61, one month after the second vaccination</time_frame>
    <description>The percentages of non-pregnant subjects with antibody concentrations above a defined threshold per serotype after the administration of two vaccine doses administered one month apart. Defined thresholds for antibody concentrations, which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Geometric Mean Concentrations (GMC) in Non-pregnant Women at One Month After the Second Vaccination.</measure>
    <time_frame>Day 61, one month after the second vaccination</time_frame>
    <description>Antibody GMC per serotype in non-pregnant women after receiving two doses of the study vaccine administered one month apart .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentages of Maternal Subjects With Antibody Concentrations Above a Defined Threshold at Day of Delivery.</measure>
    <time_frame>Day of delivery</time_frame>
    <description>The percentages of maternal subjects with antibody concentrations above a defined threshold per serotype following the administration of one of three different doses of the study vaccine or placebo.Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody GMC in Maternal Subjects at Day of Delivery</measure>
    <time_frame>Day of delivery</time_frame>
    <description>Antibody GMC per serotype in maternal subjects at day of delivery following one administration of one of three different doses of the study vaccine or placebo are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentages of Maternal Subjects With Antibody Concentrations Above a Defined Threshold Per Serotype at One Month After Vaccination.</measure>
    <time_frame>Day 31, one month after vaccination</time_frame>
    <description>The percentages of maternal subjects with antibody concentrations above a defined threshold per serotype at one month after the administration of one of three different doses of the study vaccine or placebo. Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody GMC Per Serotype in Maternal Subjects at One Month After Vaccination</measure>
    <time_frame>day 31</time_frame>
    <description>Antibody GMC per serotype in maternal subjects at one month after the administration of one of three different doses of the study vaccine or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Year After the First Vaccination.</measure>
    <time_frame>Day 361, one year after the first vaccination</time_frame>
    <description>The percentage of non-pregnant subjects with antibody concentrations above a defined threshold per serotype after the administration of two vaccine doses one month apart. Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 mcg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody GMC in Non-pregnant Subjects at One Year After the First Vaccination</measure>
    <time_frame>Day 361, one year after the first vaccination</time_frame>
    <description>Antibody GMC per serotype in non-pregnant subjects after receiving two doses of the study vaccine administered one month apart, at one year after first vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Non-pregnant Subjects Reporting Solicited and Unsolicited Adverse Events</measure>
    <time_frame>Day 61</time_frame>
    <description>Number of non-pregnant subjects reporting solicited and unsolicited adverse events following 2 injections (1 month apart) of the trivalent GBS vaccine at a dose of 20/20/20 μg with aluminum at one month after second vaccination are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Subjects Reporting Solicited and Unsolicited Adverse Events</measure>
    <time_frame>From day 1 to one year after delivery</time_frame>
    <description>Number of maternal subjects reporting solicited and unsolicited adverse events following the administration of either one of three different doses of the study vaccine or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody GMC Per Serotype at Different Time Points in Infants</measure>
    <time_frame>Day 4, day 43 and day 91 after birth</time_frame>
    <description>Antibody GMC per serotype on the day of birth, at 6 weeks and 3 months of age in infants born from women who received either one of three different doses of the study vaccine or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants Reporting Serious Adverse Events</measure>
    <time_frame>one year after birth</time_frame>
    <description>Number of infants born from women who received either one of three different doses of the study vaccine or placebo who reported serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Streptococcal Infections</condition>
  <arm_group>
    <arm_group_label>1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placebo - Sterile saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-Pregnant Women who received two injection of saline solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: GBS Trivalent Vaccine - 5/5/5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: Placebo - Sterile saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pregnant Women who received one injection of saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B Streptococcus Trivalent Vaccine - 20/20/20 μg</intervention_name>
    <description>Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.</description>
    <arm_group_label>1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Subjects received two injection of saline solution.</description>
    <arm_group_label>2: Placebo - Sterile saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg</intervention_name>
    <description>Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.</description>
    <arm_group_label>3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg</intervention_name>
    <description>Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.</description>
    <arm_group_label>4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B Streptococcus Trivalent Vaccine - 5/5/5 μg</intervention_name>
    <description>Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.</description>
    <arm_group_label>5: GBS Trivalent Vaccine - 5/5/5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>Subjects received one injection of saline solution.</description>
    <arm_group_label>6: Placebo - Sterile saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1 (Non Pregnant Women): Healthy females 18-40 years of age inclusive.

          -  Group 2 (Healthy Pregnant Women): Healthy pregnant women 18-40 yrs of age (between
             28-35 weeks gestation)

        Exclusion Criteria:

          -  Group 1 (Non Pregnant Women): Pregnant or nursing; History of severe allergy to
             previous vaccines; Known HIV positive

          -  Group 2 (Healthy Pregnant Women): History of severe allergy to previous vaccines;
             Known HIV positive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Chris Hani Rd, Soweto</city>
        <state>Johannesburg</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <results_first_submitted>December 17, 2013</results_first_submitted>
  <results_first_submitted_qc>April 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Group B streptococcus</keyword>
  <keyword>GBS</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Prevention of group B streptococcus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
          <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
        </group>
        <group group_id="P2">
          <title>Non-pregnant/Placebo</title>
          <description>Non-pregnant women received two injections of saline solution</description>
        </group>
        <group group_id="P3">
          <title>Pregnant 0.5/0.5/0.5 μg</title>
          <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="P4">
          <title>Pregnant 2.5/2.5/2.5 μg</title>
          <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="P5">
          <title>Pregnant 5/5/5 μg</title>
          <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="P6">
          <title>Pregnant/Placebo</title>
          <description>Pregnant women who received one injection of saline solution</description>
        </group>
        <group group_id="P7">
          <title>Infants 0.5/0.5/0.5 μg</title>
          <description>Infants born from women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="P8">
          <title>Infants 2.5/2.5/2.5 μg</title>
          <description>Infants born from women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="P9">
          <title>Infants 5/5/5 μg</title>
          <description>Infants born from women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="P10">
          <title>Infants / Placebo</title>
          <description>Infants born from women who received saline solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="80"/>
                <participants group_id="P6" count="80"/>
                <participants group_id="P7" count="80"/>
                <participants group_id="P8" count="80"/>
                <participants group_id="P9" count="76"/>
                <participants group_id="P10" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="74"/>
                <participants group_id="P6" count="76"/>
                <participants group_id="P7" count="74"/>
                <participants group_id="P8" count="76"/>
                <participants group_id="P9" count="71"/>
                <participants group_id="P10" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was done on the all enrolled population.</population>
      <group_list>
        <group group_id="B1">
          <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
          <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
        </group>
        <group group_id="B2">
          <title>Non-pregnant/Placebo</title>
          <description>Non-pregnant women received two injections of saline solution</description>
        </group>
        <group group_id="B3">
          <title>Pregnant 0.5/0.5/0.5 μg</title>
          <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="B4">
          <title>Pregnant 2.5/2.5/2.5 μg</title>
          <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="B5">
          <title>Pregnant 5/5/5 μg</title>
          <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="B6">
          <title>Pregnant/Placebo</title>
          <description>Pregnant women who received one injection of saline solution</description>
        </group>
        <group group_id="B7">
          <title>Infants 0.5/0.5/0.5 μg</title>
          <description>Infants born from women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="B8">
          <title>Infants 2.5/2.5/2.5 μg</title>
          <description>Infants born from women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="B9">
          <title>Infants 5/5/5 μg</title>
          <description>Infants born from women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="B10">
          <title>Infants / Placebo</title>
          <description>Infants born from women who received one injection of saline solution</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="80"/>
            <count group_id="B6" value="80"/>
            <count group_id="B7" value="80"/>
            <count group_id="B8" value="80"/>
            <count group_id="B9" value="76"/>
            <count group_id="B10" value="81"/>
            <count group_id="B11" value="697"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Non pregnant subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="5.0"/>
                    <measurement group_id="B2" value="29.4" spread="5.1"/>
                    <measurement group_id="B3" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B4" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B5" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B6" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B7" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B8" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B9" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B10" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B11" value="28.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B2" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B3" value="25.3" spread="5.2"/>
                    <measurement group_id="B4" value="25.3" spread="5.2"/>
                    <measurement group_id="B5" value="24.2" spread="4.7"/>
                    <measurement group_id="B6" value="25.7" spread="5.4"/>
                    <measurement group_id="B7" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B8" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B9" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B10" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B11" value="25.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B2" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B3" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B4" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B5" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B6" value="NA">presented elsewhere</measurement>
                    <measurement group_id="B7" value="3.0" spread="3.3"/>
                    <measurement group_id="B8" value="4.0" spread="7.8"/>
                    <measurement group_id="B9" value="5.5" spread="16.9"/>
                    <measurement group_id="B10" value="3.5" spread="8.8"/>
                    <measurement group_id="B11" value="4.0" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="80"/>
                    <measurement group_id="B7" value="45"/>
                    <measurement group_id="B8" value="38"/>
                    <measurement group_id="B9" value="33"/>
                    <measurement group_id="B10" value="48"/>
                    <measurement group_id="B11" value="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="42"/>
                    <measurement group_id="B9" value="43"/>
                    <measurement group_id="B10" value="33"/>
                    <measurement group_id="B11" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="80"/>
                    <measurement group_id="B7" value="80"/>
                    <measurement group_id="B8" value="80"/>
                    <measurement group_id="B9" value="76"/>
                    <measurement group_id="B10" value="81"/>
                    <measurement group_id="B11" value="697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentages of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Month After the Second Vaccination.</title>
        <description>The percentages of non-pregnant subjects with antibody concentrations above a defined threshold per serotype after the administration of two vaccine doses administered one month apart. Defined thresholds for antibody concentrations, which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
        <time_frame>Day 61, one month after the second vaccination</time_frame>
        <population>Full Analysis Set (FAS) – primary, non-pregnant subjects, i.e. all enrolled subjects who provided at least one evaluable serum sample result at Day 1 (prior to vaccination) and Day 61</population>
        <group_list>
          <group group_id="O1">
            <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
            <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
          </group>
          <group group_id="O2">
            <title>Non-pregnant/Placebo</title>
            <description>Non-pregnant women received two injections of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentages of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Month After the Second Vaccination.</title>
          <description>The percentages of non-pregnant subjects with antibody concentrations above a defined threshold per serotype after the administration of two vaccine doses administered one month apart. Defined thresholds for antibody concentrations, which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
          <population>Full Analysis Set (FAS) – primary, non-pregnant subjects, i.e. all enrolled subjects who provided at least one evaluable serum sample result at Day 1 (prior to vaccination) and Day 61</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia &gt;=1 μg/mL (N=34, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="76" upper_limit="98"/>
                    <measurement group_id="O2" value="37" lower_limit="16" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=2 μg/mL (N=34, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="76" upper_limit="98"/>
                    <measurement group_id="O2" value="32" lower_limit="13" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=3 μg/mL (N=34, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="73" upper_limit="97"/>
                    <measurement group_id="O2" value="26" lower_limit="9" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=5 μg/mL (N=34, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="62" upper_limit="91"/>
                    <measurement group_id="O2" value="16" lower_limit="3" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=8 μg/mL (N=34, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="59" upper_limit="89"/>
                    <measurement group_id="O2" value="16" lower_limit="3" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=1 μg/mL (N=33, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="54" upper_limit="87"/>
                    <measurement group_id="O2" value="24" lower_limit="7" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=2 μg/mL (N=33, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="48" upper_limit="82"/>
                    <measurement group_id="O2" value="12" lower_limit="1" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=3 μg/mL (N=33, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="45" upper_limit="80"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=5 μg/mL (N=33, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="25" upper_limit="61"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=8 μg/mL (N=33, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="23" upper_limit="58"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="73" upper_limit="97"/>
                    <measurement group_id="O2" value="37" lower_limit="16" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="51" upper_limit="83"/>
                    <measurement group_id="O2" value="21" lower_limit="6" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=3 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="45" upper_limit="79"/>
                    <measurement group_id="O2" value="21" lower_limit="6" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="34" upper_limit="69"/>
                    <measurement group_id="O2" value="11" lower_limit="1" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=8 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="31" upper_limit="66"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Geometric Mean Concentrations (GMC) in Non-pregnant Women at One Month After the Second Vaccination.</title>
        <description>Antibody GMC per serotype in non-pregnant women after receiving two doses of the study vaccine administered one month apart .</description>
        <time_frame>Day 61, one month after the second vaccination</time_frame>
        <population>FAS - primary, non-pregnant subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
            <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
          </group>
          <group group_id="O2">
            <title>Non-pregnant/Placebo</title>
            <description>Non-pregnant women received two injections of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Geometric Mean Concentrations (GMC) in Non-pregnant Women at One Month After the Second Vaccination.</title>
          <description>Antibody GMC per serotype in non-pregnant women after receiving two doses of the study vaccine administered one month apart .</description>
          <population>FAS - primary, non-pregnant subjects</population>
          <units>concentrations (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia (N=34, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="26" upper_limit="62"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.49" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib (N=33, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.94" upper_limit="9.56"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.12" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6.43" upper_limit="19"/>
                    <measurement group_id="O2" value="0.61" lower_limit="0.29" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentages of Maternal Subjects With Antibody Concentrations Above a Defined Threshold Per Serotype at One Month After Vaccination.</title>
        <description>The percentages of maternal subjects with antibody concentrations above a defined threshold per serotype at one month after the administration of one of three different doses of the study vaccine or placebo. Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
        <time_frame>Day 31, one month after vaccination</time_frame>
        <population>FAS, secondary, maternal subjects, day 31, i.e. all enrolled subjects who provided at least one evaluable serum sample result at day 1 (prior to vaccination) and at day 31</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnant 0.5/0.5/0.5 μg</title>
            <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O2">
            <title>Pregnant 2.5/2.5/2.5 μg</title>
            <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O3">
            <title>Pregnant 5/5/5 μg</title>
            <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O4">
            <title>Pregnant/Placebo</title>
            <description>Pregnant women who received one injection of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentages of Maternal Subjects With Antibody Concentrations Above a Defined Threshold Per Serotype at One Month After Vaccination.</title>
          <description>The percentages of maternal subjects with antibody concentrations above a defined threshold per serotype at one month after the administration of one of three different doses of the study vaccine or placebo. Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
          <population>FAS, secondary, maternal subjects, day 31, i.e. all enrolled subjects who provided at least one evaluable serum sample result at day 1 (prior to vaccination) and at day 31</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>serotype Ia&gt;=1μg/mL (N=75, 74, 69, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="75" upper_limit="92"/>
                    <measurement group_id="O2" value="77" lower_limit="66" upper_limit="86"/>
                    <measurement group_id="O3" value="88" lower_limit="78" upper_limit="95"/>
                    <measurement group_id="O4" value="33" lower_limit="23" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ia&gt;=2μg/mL (N=75, 74, 69, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="68" upper_limit="87"/>
                    <measurement group_id="O2" value="77" lower_limit="66" upper_limit="86"/>
                    <measurement group_id="O3" value="81" lower_limit="70" upper_limit="90"/>
                    <measurement group_id="O4" value="27" lower_limit="17" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ia&gt;=3μg/mL (N=75, 74, 69, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="65" upper_limit="85"/>
                    <measurement group_id="O2" value="73" lower_limit="61" upper_limit="83"/>
                    <measurement group_id="O3" value="78" lower_limit="67" upper_limit="87"/>
                    <measurement group_id="O4" value="23" lower_limit="14" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ia&gt;=5μg/mL (N=75, 74, 69, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="63" upper_limit="84"/>
                    <measurement group_id="O2" value="70" lower_limit="59" upper_limit="80"/>
                    <measurement group_id="O3" value="71" lower_limit="59" upper_limit="81"/>
                    <measurement group_id="O4" value="15" lower_limit="8" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ia&gt;=8μg/mL (N=75, 74, 69, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="59" upper_limit="81"/>
                    <measurement group_id="O2" value="70" lower_limit="59" upper_limit="80"/>
                    <measurement group_id="O3" value="71" lower_limit="59" upper_limit="81"/>
                    <measurement group_id="O4" value="9" lower_limit="4" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ib&gt;=1μg/mL (N= 65, 69, 66, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="52" upper_limit="76"/>
                    <measurement group_id="O2" value="68" lower_limit="56" upper_limit="79"/>
                    <measurement group_id="O3" value="62" lower_limit="49" upper_limit="74"/>
                    <measurement group_id="O4" value="21" lower_limit="12" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ib&gt;=2μg/mL (N= 65, 69, 66, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="47" upper_limit="72"/>
                    <measurement group_id="O2" value="54" lower_limit="41" upper_limit="66"/>
                    <measurement group_id="O3" value="50" lower_limit="37" upper_limit="63"/>
                    <measurement group_id="O4" value="13" lower_limit="6" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ib&gt;=3μg/mL (N= 65, 69, 66, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="41" upper_limit="66"/>
                    <measurement group_id="O2" value="48" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="O3" value="44" lower_limit="32" upper_limit="57"/>
                    <measurement group_id="O4" value="11" lower_limit="5" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ib&gt;=5μg/mL (N= 65, 69, 66, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="35" upper_limit="60"/>
                    <measurement group_id="O2" value="43" lower_limit="32" upper_limit="56"/>
                    <measurement group_id="O3" value="36" lower_limit="25" upper_limit="49"/>
                    <measurement group_id="O4" value="10" lower_limit="4" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ib&gt;=8μg/mL (N= 65, 69, 66, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="31" upper_limit="56"/>
                    <measurement group_id="O2" value="39" lower_limit="28" upper_limit="52"/>
                    <measurement group_id="O3" value="30" lower_limit="20" upper_limit="43"/>
                    <measurement group_id="O4" value="8" lower_limit="3" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype III&gt;=1μg/mL (N= 73, 74, 68, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="58" upper_limit="80"/>
                    <measurement group_id="O2" value="65" lower_limit="53" upper_limit="76"/>
                    <measurement group_id="O3" value="57" lower_limit="45" upper_limit="69"/>
                    <measurement group_id="O4" value="13" lower_limit="6" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype III&gt;=2μg/mL (N=73, 74, 68, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="45" upper_limit="69"/>
                    <measurement group_id="O2" value="54" lower_limit="42" upper_limit="66"/>
                    <measurement group_id="O3" value="51" lower_limit="39" upper_limit="64"/>
                    <measurement group_id="O4" value="12" lower_limit="6" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype III&gt;=3μg/mL (N=73, 74, 68, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="O2" value="50" lower_limit="38" upper_limit="62"/>
                    <measurement group_id="O3" value="44" lower_limit="32" upper_limit="57"/>
                    <measurement group_id="O4" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype III&gt;=5μg/mL (N=73, 74, 68, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="30" upper_limit="53"/>
                    <measurement group_id="O2" value="43" lower_limit="32" upper_limit="55"/>
                    <measurement group_id="O3" value="32" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype III&gt;=8μg/mL (N=73, 74, 68, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="27" upper_limit="50"/>
                    <measurement group_id="O2" value="34" lower_limit="23" upper_limit="46"/>
                    <measurement group_id="O3" value="29" lower_limit="19" upper_limit="42"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentages of Maternal Subjects With Antibody Concentrations Above a Defined Threshold at Day of Delivery.</title>
        <description>The percentages of maternal subjects with antibody concentrations above a defined threshold per serotype following the administration of one of three different doses of the study vaccine or placebo.Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
        <time_frame>Day of delivery</time_frame>
        <population>FAS primary, maternal subjects, i.e. all enrolled subjects who provided at least one evaluable serum sample result at day 1 (prior to vaccination) and at delivery</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnant 0.5/0.5/0.5 μg</title>
            <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O2">
            <title>Pregnant 2.5/2.5/2.5 μg</title>
            <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O3">
            <title>Pregnant 5/5/5 μg</title>
            <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O4">
            <title>Pregnant/Placebo</title>
            <description>Pregnant women who received one injection of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentages of Maternal Subjects With Antibody Concentrations Above a Defined Threshold at Day of Delivery.</title>
          <description>The percentages of maternal subjects with antibody concentrations above a defined threshold per serotype following the administration of one of three different doses of the study vaccine or placebo.Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 μg/mL.</description>
          <population>FAS primary, maternal subjects, i.e. all enrolled subjects who provided at least one evaluable serum sample result at day 1 (prior to vaccination) and at delivery</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia &gt;= 1 μg/mL (N=76,77, 73, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="76" upper_limit="93"/>
                    <measurement group_id="O2" value="83" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O3" value="89" lower_limit="80" upper_limit="95"/>
                    <measurement group_id="O4" value="38" lower_limit="27" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;= 2 μg/mL (N=76, 77, 73, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="67" upper_limit="86"/>
                    <measurement group_id="O2" value="74" lower_limit="63" upper_limit="83"/>
                    <measurement group_id="O3" value="81" lower_limit="70" upper_limit="89"/>
                    <measurement group_id="O4" value="26" lower_limit="17" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;= 3 μg/mL (N=76, 77, 73, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64" upper_limit="84"/>
                    <measurement group_id="O2" value="71" lower_limit="60" upper_limit="81"/>
                    <measurement group_id="O3" value="77" lower_limit="65" upper_limit="86"/>
                    <measurement group_id="O4" value="21" lower_limit="13" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;= 5 μg/mL (N=76, 77, 73, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="61" upper_limit="82"/>
                    <measurement group_id="O2" value="69" lower_limit="57" upper_limit="79"/>
                    <measurement group_id="O3" value="75" lower_limit="64" upper_limit="85"/>
                    <measurement group_id="O4" value="18" lower_limit="10" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;= 8 μg/mL (N=76, 77, 73, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="53" upper_limit="75"/>
                    <measurement group_id="O2" value="64" lower_limit="52" upper_limit="74"/>
                    <measurement group_id="O3" value="71" lower_limit="59" upper_limit="81"/>
                    <measurement group_id="O4" value="9" lower_limit="4" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;= 1 μg/mL (N=69, 74, 71, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="45" upper_limit="70"/>
                    <measurement group_id="O2" value="65" lower_limit="53" upper_limit="76"/>
                    <measurement group_id="O3" value="65" lower_limit="53" upper_limit="76"/>
                    <measurement group_id="O4" value="14" lower_limit="6" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;= 2 μg/mL (69, 74, 71, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="40" upper_limit="64"/>
                    <measurement group_id="O2" value="51" lower_limit="39" upper_limit="63"/>
                    <measurement group_id="O3" value="48" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="O4" value="10" lower_limit="4" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;= 3 μg/mL (N=69, 74, 71, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="32" upper_limit="56"/>
                    <measurement group_id="O2" value="49" lower_limit="37" upper_limit="61"/>
                    <measurement group_id="O3" value="42" lower_limit="31" upper_limit="55"/>
                    <measurement group_id="O4" value="10" lower_limit="4" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;= 5 μg/mL (N=69, 74, 71, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="29" upper_limit="53"/>
                    <measurement group_id="O2" value="41" lower_limit="29" upper_limit="53"/>
                    <measurement group_id="O3" value="37" lower_limit="25" upper_limit="49"/>
                    <measurement group_id="O4" value="9" lower_limit="3" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;= 8 μg/mL (N=69, 74, 71, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="25" upper_limit="49"/>
                    <measurement group_id="O2" value="36" lower_limit="26" upper_limit="48"/>
                    <measurement group_id="O3" value="32" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ill &gt;= 1 μg/mL (N=74, 77, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="57" upper_limit="79"/>
                    <measurement group_id="O2" value="66" lower_limit="55" upper_limit="77"/>
                    <measurement group_id="O3" value="64" lower_limit="52" upper_limit="75"/>
                    <measurement group_id="O4" value="14" lower_limit="7" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ill &gt;= 2 μg/mL (N=74, 77, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="50" upper_limit="73"/>
                    <measurement group_id="O2" value="53" lower_limit="42" upper_limit="65"/>
                    <measurement group_id="O3" value="51" lower_limit="39" upper_limit="63"/>
                    <measurement group_id="O4" value="9" lower_limit="4" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ill &gt;= 3 μg/mL (N=74, 77, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="37" upper_limit="61"/>
                    <measurement group_id="O2" value="44" lower_limit="33" upper_limit="56"/>
                    <measurement group_id="O3" value="42" lower_limit="31" upper_limit="55"/>
                    <measurement group_id="O4" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ill &gt;= 5 μg/mL (N=74, 77, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="28" upper_limit="51"/>
                    <measurement group_id="O2" value="49" lower_limit="29" upper_limit="52"/>
                    <measurement group_id="O3" value="36" lower_limit="25" upper_limit="48"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ill &gt;= 8 μg/mL (N=74, 77, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="23" upper_limit="46"/>
                    <measurement group_id="O2" value="35" lower_limit="25" upper_limit="47"/>
                    <measurement group_id="O3" value="29" lower_limit="19" upper_limit="41"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody GMC in Maternal Subjects at Day of Delivery</title>
        <description>Antibody GMC per serotype in maternal subjects at day of delivery following one administration of one of three different doses of the study vaccine or placebo are reported.</description>
        <time_frame>Day of delivery</time_frame>
        <population>FAS primary, maternal subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnant 0.5/0.5/0.5 μg</title>
            <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O2">
            <title>Pregnant 2.5/2.5/2.5 μg</title>
            <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O3">
            <title>Pregnant 5/5/5 μg</title>
            <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O4">
            <title>Pregnant/Placebo</title>
            <description>Pregnant women who received one injection of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody GMC in Maternal Subjects at Day of Delivery</title>
          <description>Antibody GMC per serotype in maternal subjects at day of delivery following one administration of one of three different doses of the study vaccine or placebo are reported.</description>
          <population>FAS primary, maternal subjects</population>
          <units>Concentration (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia (N= 76, 77, 73, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" lower_limit="6.6" upper_limit="15"/>
                    <measurement group_id="O2" value="14" lower_limit="9.19" upper_limit="21"/>
                    <measurement group_id="O3" value="24" lower_limit="16" upper_limit="36"/>
                    <measurement group_id="O4" value="0.67" lower_limit="0.46" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib (N=69, 74, 71, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.61" upper_limit="3.88"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.74" upper_limit="6.76"/>
                    <measurement group_id="O3" value="2.93" lower_limit="1.79" upper_limit="4.77"/>
                    <measurement group_id="O4" value="0.38" lower_limit="0.25" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III (N=74, 77, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" lower_limit="1.8" upper_limit="3.85"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2.52" upper_limit="5.31"/>
                    <measurement group_id="O3" value="2.83" lower_limit="1.92" upper_limit="4.17"/>
                    <measurement group_id="O4" value="0.25" lower_limit="0.18" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody GMC Per Serotype in Maternal Subjects at One Month After Vaccination</title>
        <description>Antibody GMC per serotype in maternal subjects at one month after the administration of one of three different doses of the study vaccine or placebo.</description>
        <time_frame>day 31</time_frame>
        <population>FAS, secondary, maternal subjects, day 31</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnant 0.5/0.5/0.5 μg</title>
            <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O2">
            <title>Pregnant 2.5/2.5/2.5 μg</title>
            <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O3">
            <title>Pregnant 5/5/5 μg</title>
            <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O4">
            <title>Pregnant/Placebo</title>
            <description>Pregnant women who received one injection of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody GMC Per Serotype in Maternal Subjects at One Month After Vaccination</title>
          <description>Antibody GMC per serotype in maternal subjects at one month after the administration of one of three different doses of the study vaccine or placebo.</description>
          <population>FAS, secondary, maternal subjects, day 31</population>
          <units>concentration (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>serotype Ia (N=75, 74, 69, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8.27" upper_limit="21"/>
                    <measurement group_id="O2" value="15" lower_limit="9.54" upper_limit="25"/>
                    <measurement group_id="O3" value="26" lower_limit="16" upper_limit="43"/>
                    <measurement group_id="O4" value="0.62" lower_limit="0.41" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ib (N=65, 69, 66, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" lower_limit="1.68" upper_limit="4.59"/>
                    <measurement group_id="O2" value="5.42" lower_limit="3.21" upper_limit="9.18"/>
                    <measurement group_id="O3" value="3.66" lower_limit="2.06" upper_limit="6.52"/>
                    <measurement group_id="O4" value="0.3" lower_limit="0.19" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype III (N=73, 74, 68, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="1.96" upper_limit="4.62"/>
                    <measurement group_id="O2" value="4.11" lower_limit="2.68" upper_limit="6.31"/>
                    <measurement group_id="O3" value="2.77" lower_limit="1.75" upper_limit="4.37"/>
                    <measurement group_id="O4" value="0.19" lower_limit="0.13" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Year After the First Vaccination.</title>
        <description>The percentage of non-pregnant subjects with antibody concentrations above a defined threshold per serotype after the administration of two vaccine doses one month apart. Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 mcg/mL.</description>
        <time_frame>Day 361, one year after the first vaccination</time_frame>
        <population>FAS persistence, non-pregnant subjects, i.e. all enrolled subjects who provided at least one evaluable serum sample result at day 1 (prior to vaccination) and day 361.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
            <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
          </group>
          <group group_id="O2">
            <title>Non-pregnant/Placebo</title>
            <description>Non-pregnant women received two injections of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Year After the First Vaccination.</title>
          <description>The percentage of non-pregnant subjects with antibody concentrations above a defined threshold per serotype after the administration of two vaccine doses one month apart. Antibody concentrations which exceed pre-defined serotype specific ELISA values are 1, 2, 3, 5 and 8 mcg/mL.</description>
          <population>FAS persistence, non-pregnant subjects, i.e. all enrolled subjects who provided at least one evaluable serum sample result at day 1 (prior to vaccination) and day 361.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia &gt;=1μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="71" upper_limit="95"/>
                    <measurement group_id="O2" value="30" lower_limit="12" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=2μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="59" upper_limit="88"/>
                    <measurement group_id="O2" value="30" lower_limit="12" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=3μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="59" upper_limit="88"/>
                    <measurement group_id="O2" value="25" lower_limit="9" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=5μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="53" upper_limit="84"/>
                    <measurement group_id="O2" value="15" lower_limit="3" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia &gt;=8μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="45" upper_limit="78"/>
                    <measurement group_id="O2" value="10" lower_limit="1" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=1μg/mL (N=37, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="65" upper_limit="92"/>
                    <measurement group_id="O2" value="21" lower_limit="6" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=2μg/mL (N=37, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="47" upper_limit="80"/>
                    <measurement group_id="O2" value="16" lower_limit="3" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=3μg/mL (37, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="45" upper_limit="78"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=5μg/mL (N=37, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="22" upper_limit="55"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib &gt;=8μg/mL (N=37, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=1μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="65" upper_limit="92"/>
                    <measurement group_id="O2" value="20" lower_limit="6" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=2μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="53" upper_limit="84"/>
                    <measurement group_id="O2" value="15" lower_limit="3" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=3μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="47" upper_limit="80"/>
                    <measurement group_id="O2" value="15" lower_limit="3" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=5μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="37" upper_limit="71"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III &gt;=8μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="25" upper_limit="58"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody GMC in Non-pregnant Subjects at One Year After the First Vaccination</title>
        <description>Antibody GMC per serotype in non-pregnant subjects after receiving two doses of the study vaccine administered one month apart, at one year after first vaccination.</description>
        <time_frame>Day 361, one year after the first vaccination</time_frame>
        <population>FAS persistence, non-pregnant subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
            <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
          </group>
          <group group_id="O2">
            <title>Non-pregnant/Placebo</title>
            <description>Non-pregnant women received two injections of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody GMC in Non-pregnant Subjects at One Year After the First Vaccination</title>
          <description>Antibody GMC per serotype in non-pregnant subjects after receiving two doses of the study vaccine administered one month apart, at one year after first vaccination.</description>
          <population>FAS persistence, non-pregnant subjects</population>
          <units>concentration (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>serotype Ia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="9.86" upper_limit="22"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.51" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype Ib (N=37, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" lower_limit="3.49" upper_limit="7.98"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.23" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serotype III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" lower_limit="4.5" upper_limit="11"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.17" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Non-pregnant Subjects Reporting Solicited and Unsolicited Adverse Events</title>
        <description>Number of non-pregnant subjects reporting solicited and unsolicited adverse events following 2 injections (1 month apart) of the trivalent GBS vaccine at a dose of 20/20/20 μg with aluminum at one month after second vaccination are reported.</description>
        <time_frame>Day 61</time_frame>
        <population>Safety set, solicited and unsolicited reactogenicity, non-pregnant subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
            <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
          </group>
          <group group_id="O2">
            <title>Non Pregnant/Placebo</title>
            <description>Non pregnant women received two injections of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Non-pregnant Subjects Reporting Solicited and Unsolicited Adverse Events</title>
          <description>Number of non-pregnant subjects reporting solicited and unsolicited adverse events following 2 injections (1 month apart) of the trivalent GBS vaccine at a dose of 20/20/20 μg with aluminum at one month after second vaccination are reported.</description>
          <population>Safety set, solicited and unsolicited reactogenicity, non-pregnant subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Solicited adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Subjects Reporting Solicited and Unsolicited Adverse Events</title>
        <description>Number of maternal subjects reporting solicited and unsolicited adverse events following the administration of either one of three different doses of the study vaccine or placebo.</description>
        <time_frame>From day 1 to one year after delivery</time_frame>
        <population>Safety set, solicited and unsolicited reactogenicity, maternal subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnant 0.5/0.5/0.5 μg</title>
            <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O2">
            <title>Pregnant 2.5/2.5/2.5 μg</title>
            <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O3">
            <title>Pregnant 5/5/5 μg</title>
            <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O4">
            <title>Pregnant/Placebo</title>
            <description>Pregnant women who received one injection of saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Subjects Reporting Solicited and Unsolicited Adverse Events</title>
          <description>Number of maternal subjects reporting solicited and unsolicited adverse events following the administration of either one of three different doses of the study vaccine or placebo.</description>
          <population>Safety set, solicited and unsolicited reactogenicity, maternal subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>solicited adverse events (N=80, 80, 79, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unsolicited adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody GMC Per Serotype at Different Time Points in Infants</title>
        <description>Antibody GMC per serotype on the day of birth, at 6 weeks and 3 months of age in infants born from women who received either one of three different doses of the study vaccine or placebo.</description>
        <time_frame>Day 4, day 43 and day 91 after birth</time_frame>
        <population>Per Protocol Set, infants, i.e. all subjects who provided evaluable serum samples at birth, study day 43, study day 91 and within the required time frames</population>
        <group_list>
          <group group_id="O1">
            <title>Infants 0.5/0.5/0.5 μg</title>
            <description>Infants born from women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O2">
            <title>Infants 2.5/2.5/2.5 μg</title>
            <description>Infants born from women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O3">
            <title>Infants 5/5/5 μg</title>
            <description>Infants born from women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O4">
            <title>Infants / Placebo</title>
            <description>Infants born from women who received saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody GMC Per Serotype at Different Time Points in Infants</title>
          <description>Antibody GMC per serotype on the day of birth, at 6 weeks and 3 months of age in infants born from women who received either one of three different doses of the study vaccine or placebo.</description>
          <population>Per Protocol Set, infants, i.e. all subjects who provided evaluable serum samples at birth, study day 43, study day 91 and within the required time frames</population>
          <units>concentration (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia (day 4; N=75, 76, 69, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" lower_limit="4.03" upper_limit="11"/>
                    <measurement group_id="O2" value="6.52" lower_limit="3.96" upper_limit="11"/>
                    <measurement group_id="O3" value="12" lower_limit="7.21" upper_limit="20"/>
                    <measurement group_id="O4" value="0.49" lower_limit="0.34" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia (day 43; N= 75, 76, 68, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="2.01" upper_limit="5.13"/>
                    <measurement group_id="O2" value="2.95" lower_limit="1.85" upper_limit="4.7"/>
                    <measurement group_id="O3" value="5.54" lower_limit="3.38" upper_limit="9.06"/>
                    <measurement group_id="O4" value="0.31" lower_limit="0.23" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia (day 91; N=71, 75, 64, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.31" upper_limit="2.95"/>
                    <measurement group_id="O2" value="2.22" lower_limit="1.49" upper_limit="3.29"/>
                    <measurement group_id="O3" value="2.78" lower_limit="1.81" upper_limit="4.26"/>
                    <measurement group_id="O4" value="0.38" lower_limit="0.29" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib (day 4; N=71, 71, 66, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="0.68" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.72" lower_limit="1.02" upper_limit="2.92"/>
                    <measurement group_id="O3" value="1.39" lower_limit="0.81" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.21" lower_limit="0.14" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib (day 43; N=72, 77, 67, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.47" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.57" upper_limit="1.35"/>
                    <measurement group_id="O3" value="0.67" lower_limit="0.42" upper_limit="1.07"/>
                    <measurement group_id="O4" value="0.15" lower_limit="0.11" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib (day 91; N= 74, 73, 66, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.61" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.77" upper_limit="1.51"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.59" upper_limit="1.19"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.39" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III (day 4; N= 57, 64, 58, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="1.26" upper_limit="3.54"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.41" upper_limit="3.76"/>
                    <measurement group_id="O3" value="1.72" lower_limit="1.03" upper_limit="2.87"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.19" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III (day 43; N= 64, 75, 61, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.53" upper_limit="1.27"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.59" upper_limit="1.31"/>
                    <measurement group_id="O3" value="0.68" lower_limit="0.43" upper_limit="1.06"/>
                    <measurement group_id="O4" value="0.16" lower_limit="0.12" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III (day 91; N= 63, 63, 57, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.42" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.69" lower_limit="0.48" upper_limit="0.98"/>
                    <measurement group_id="O3" value="0.51" lower_limit="0.35" upper_limit="0.74"/>
                    <measurement group_id="O4" value="0.27" lower_limit="0.21" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants Reporting Serious Adverse Events</title>
        <description>Number of infants born from women who received either one of three different doses of the study vaccine or placebo who reported serious adverse events</description>
        <time_frame>one year after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infants 0.5/0.5/0.5 μg</title>
            <description>Infants born from women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O2">
            <title>Infants 2.5/2.5/2.5 μg</title>
            <description>Infants born from women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O3">
            <title>Infants 5/5/5 μg</title>
            <description>Infants born from women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
          </group>
          <group group_id="O4">
            <title>Infants / Placebo</title>
            <description>Infants born from women who received saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants Reporting Serious Adverse Events</title>
          <description>Number of infants born from women who received either one of three different doses of the study vaccine or placebo who reported serious adverse events</description>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected from day 1 to 7 after vaccination; unsolicited AEs and SAEs were collected from day 1 to day 361.</time_frame>
      <desc>Analyses was done on the Safety Population. Solicited AEs were collected through systematic assessment, unsolicited AEs were collected through non-systematic assesment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Non-pregnant 20/20/20 μg +Aluminum Hydroxide</title>
          <description>Non-pregnant women who received two injections of 20/20/20 μg dose of trivalent GBS vaccine with aluminum</description>
        </group>
        <group group_id="E2">
          <title>Non-pregnant/Placebo</title>
          <description>Non-pregnant women received two injections of saline solution</description>
        </group>
        <group group_id="E3">
          <title>Pregnant 0.5/0.5/0.5 μg</title>
          <description>Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="E4">
          <title>Pregnant 2.5/2.5/2.5 μg</title>
          <description>Pregnant women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="E5">
          <title>Pregnant 5/5/5 μg</title>
          <description>Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="E6">
          <title>Pregnant/Placebo</title>
          <description>Pregnant women who received one injection of saline solution</description>
        </group>
        <group group_id="E7">
          <title>Infants 0.5/0.5/0.5 μg</title>
          <description>Infants born from women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="E8">
          <title>Infants 2.5/2.5/2.5 μg</title>
          <description>Infants born from women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="E9">
          <title>Infants 5/5/5 μg</title>
          <description>Infants born from women who received one injection of 5/5/5 μg dose of non adjuvanted trivalent GBS vaccine</description>
        </group>
        <group group_id="E10">
          <title>Infants / Placebo</title>
          <description>Infants born from women who received one injection of saline solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia foetal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>congenital pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>strabism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>bullous impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>chorioamnionitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>eczema herpeticum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>postpartum sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>umbilical sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>urinary tract infection bacteria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>perineal laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>vulvovaginal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>coagulation factor IX level decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>convulsion neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>breech presentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>failed induction of labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>false labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>foetal hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>haemorrage in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>labour complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>postpartum haemorrage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>premature labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>prolonged labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>prolonged pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>retained product of conception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>umbilical cord prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal haemorrage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>neonathal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>erythema toxicum neonatorum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>labour induction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>subgaleal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="71" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="44" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="49" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="48" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="51" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>injection site warmth</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>induration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="24" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other disclosure agreement: the terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

